Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Loza, Matthew J ^a   Watt, Rosemary ^a   Baribaud, Frédéric ^a   Barnathan, Elliot S ^a   Rennard, Stephen I ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Biological biomarkers; Chronic obstructive pulmonary disease; Inflammation; Infliximab; Tumor necrosis factor alpha

Indexed keywords

ACUTE PHASE PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CD40 LIGAND; CELL PROTEIN; CORTICOSTEROID; CREATINE KINASE MB; EPIDERMAL GROWTH FACTOR; INFLIXIMAB; MYOGLOBIN; NEUTROPHIL ASSOCIATED PROTEIN; PLACEBO; PROTEIN; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CD40 ANTIGEN; CREATINE KINASE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEART DISEASE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; HOSPITALIZATION; MIDDLE AGED;

ACUTE-PHASE PROTEINS; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; BRAIN-DERIVED NEUROTROPHIC FACTOR; C-REACTIVE PROTEIN; CREATINE KINASE; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856422868     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-12     Document Type: Article

References (35)

1. Wust RC, Degens H. Factors contributing to muscle wasting and dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis 2007, 2(3):289-300. 2695204, 18229567.
2. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94(7):3195-3199. 10.1073/pnas.94.7.3195, 20345, 9096369.
3. Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(2):420-422.
4. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(2):349-355.
5. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994, 150(5 Pt 1):1453-1455.
6. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(6 Pt 1):1791-1797.
7. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996, 153(2):633-637.
8. Sulkowska M, Sulkowski S, Terlikowski S, Nowak HF. Tumor necrosis factor-alpha induces emphysema-like pulmonary tissue rebuilding. Changes in type II alveolar epithelial cells. Pol J Pathol 1997, 48(3):179-188.
9. Zheng T, Kang MJ, Crothers K, Zhu Z, Liu W, Lee CG, Rabach LA, Chapman HA, Homer RJ, Aldous D, De Sanctis GT, Underwood S, Graupe M, Flavell RA, Schmidt JA, Elias JA. Role of cathepsin S-dependent epithelial cell apoptosis in IFN-gamma-induced alveolar remodeling and pulmonary emphysema. J Immunol 2005, 174(12):8106-8115.
10. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(6):1304-1309.
11. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, . The Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343(22):1594-1602. 10.1056/NEJM200011303432202, 11096166, The Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
12. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64(8):1150-1157. 10.1136/ard.2004.032268, 1755609, 15677701.
13. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350(9):876-885. 10.1056/NEJMoa030815, 14985485.
14. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohue JF, Watt R, Lo KH, Schlenker-Herceg R, Barnathan ES, Murray J. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(9):926-934. 10.1164/rccm.200607-995OC, 17290043.
15. Loza MJ, Brodmerkel C, Du Bois RM, Judson MA, Costabel U, Drent M, Kavuru M, Flavin S, Lo KH, Barnathan ES, Baughman RP. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol 2011, 18(6):931-939. 10.1128/CVI.00337-10, 3122612, 21508170.
16. Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007, 62(7):595-601. 10.1136/thx.2006.064428, 2117244, 17356059.
17. Elliott MJ, Woo P, Charles P, Long-Fox A, Woody JN, Maini RN. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol 1997, 36(5):589-593. 10.1093/rheumatology/36.5.589, 9189062.
18. Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, Devogelaer JP, Houssiau FA. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Ann Rheum Dis 2004, 63(9):1069-1074. 10.1136/ard.2003.012914, 1755125, 15308515.
19. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008, 67(4):511-517. 2564765, 17644552.
20. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, Mack M, Baker DG, Rahman MU. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol 2009, 36(7):1371-1379. 10.3899/jrheum.080755, 19487269.
21. Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010, 27(1):49-56.
22. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107(11):1514-1519. 10.1161/01.CIR.0000056767.69054.B3, 12654609.
23. Piehl-Aulin K, Jones I, Lindvall B, Magnuson A, Abdel-Halim SM. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease. Respiration 2009, 78(2):191-196. 10.1159/000207793, 19270439.
24. Ashitani J, Mukae H, Arimura Y, Matsukura S. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med 2002, 41(3):181-185. 10.2169/internalmedicine.41.181, 11929177.
25. Kythreotis P, Kokkini A, Avgeropoulou S, Hadjioannou A, Anastasakou E, Rasidakis A, Bakakos P. Plasma leptin and insulin-like growth factor I levels during acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med 2009, 9:11. 10.1186/1471-2466-9-11, 2670813, 19344528.
26. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164(6):1008-1011.
27. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J Suppl 2001, 34:50s-59s.
28. de Boer WI, Hau CM, van Schadewijk A, Stolk J, van Krieken JH, Hiemstra PS. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 2006, 125(2):184-192.
29. Mata M, Sarria B, Buenestado A, Cortijo J, Cerda M, Morcillo EJ. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax 2005, 60(2):144-152. 10.1136/thx.2004.025692, 1747298, 15681504.
30. Takeyama K, Jung B, Shim JJ, Burgel PR, Dao-Pick T, Ueki IF, Protin U, Kroschel P, Nadel JA. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am J Physiol Lung Cell Mol Physiol 2001, 280(1):L165-172.
31. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-2653. 10.1056/NEJMoa032158, 15215480.
32. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003, 114(9):758-762. 10.1016/S0002-9343(03)00185-2, 12829203.
33. Barreiro E, Gea J, Matar G, Hussain SN. Expression and carbonylation of creatine kinase in the quadriceps femoris muscles of patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2005, 33(6):636-642. 10.1165/rcmb.2005-0114OC, 16166745.
34. Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M, Magnussen H. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 138(1):32-38.
35. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007, 131(5):1557-1566. 10.1378/chest.06-2179, 17494805.